SIREN : 808837496
SO INJECT & CO is a French company founded 11 years ago, specialized in the sector Activités des sociétés holding. Based in BAILLY-ROMAINVILLIERS (77700), this company of category PME shows in 2025 a revenue of 289 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 289 337 € | 292 265 € | 333 343 € | N/C | 389 142 € | 427 580 € | 366 412 € | 77 158 € |
| Net income | 165 251 € | 152 507 € | 170 290 € | 42 971 € | 41 486 € | 44 926 € | 47 292 € | 1 195 012 € |
| EBITDA | 70 494 € | -5 602 € | 67 570 € | N/C | 66 909 € | 78 908 € | 80 950 € | 22 872 € |
| Net margin | 57.1% | 52.2% | 51.1% | N/C | 10.7% | 10.5% | 12.9% | 1548.8% |
In 2025, SO INJECT & CO achieves revenue of 289 k€. Over the period 2015-2025, the company shows strong growth with a CAGR (compound annual growth rate) of +14.1%. Slight decline of -1% vs 2024. After deducting consumption (0 €), gross margin stands at 289 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 70 k€, representing 24.4% of revenue. Positive scissor effect: EBITDA margin improves by +26.3 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 165 k€, i.e. 57.1% of revenue. This profit can be retained or distributed to shareholders.
289 337 €
289 337 €
70 494 €
70 569 €
165 251 €
24.4%
The debt ratio (= Financial debt / Equity x 100) stands at 13%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 87%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.7 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 57.1% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
12.675%
86.555%
57.114%
1.668
In 2025, the debt ratio of SO INJECT & CO (12.68) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2025, the financial autonomy of SO INJECT & CO (86.6%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2025, the repayment capacity of SO INJECT & CO (1.67) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 8.82. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 26.6x. Operating income very largely covers interest expenses: high safety margin.
8.82
26.597
In 2025, the liquidity ratio of SO INJECT & CO (8.82) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2025, the interest coverage of SO INJECT & CO (26.6x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 84 days. Excellent situation: suppliers finance 84 days of the operating cycle (retail model). WCR is negative (-70 days): operations structurally generate cash. Notable WCR improvement over the period (-160%), freeing up cash.
-56 291 €
0 j
84 j
0 j
-70 j
Indicative estimate only : the number of comparable transactions in this sector is limited (20 transactions). This range of 111 376€ to 1 029 712€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 20 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare SO INJECT & CO with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of SO INJECT & CO in 2025 is 289 k€.
Yes, SO INJECT & CO generated a net profit of 165 k€ in 2025.
The headquarters of SO INJECT & CO is located in BAILLY-ROMAINVILLIERS (77700), in the department Seine-et-Marne.
The tax return of SO INJECT & CO is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SO INJECT & CO operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.